Literature DB >> 18226907

Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.

Na Xue1, Xiaochun Yang, Rui Wu, Jing Chen, Qiaojun He, Bo Yang, Xiuyang Lu, Yongzhou Hu.   

Abstract

A new series of aryl substituted imidazol-2-one derivatives structurally related to combretastatin A-4 (CA-4) were synthesized and evaluated for their cytotoxic activities in vitro against various human cancer cell lines including MDR cell line. The cytotoxic effects of compounds 7b and 7i proved to be similar to or greater than that of docetaxel. The highly active compound 7b also exhibited excellent inhibitory activity on tumor growth in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18226907     DOI: 10.1016/j.bmc.2007.11.048

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

Review 1.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

2.  Cu(I)-catalyzed C-H alpha-amination of aryl ketones: direct synthesis of imidazolinones.

Authors:  Baoguo Zhao; Haifeng Du; Yian Shi
Journal:  J Org Chem       Date:  2009-06-05       Impact factor: 4.354

3.  Cu(I)-catalyzed sequential diamination and dehydrogenation of terminal olefins: a facile approach to imidazolinones.

Authors:  Yingguang Zhu; Yian Shi
Journal:  Chemistry       Date:  2014-09-11       Impact factor: 5.236

4.  N-Amino-imidazolin-2-one peptide mimic synthesis and conformational analysis.

Authors:  Caroline Proulx; William D Lubell
Journal:  Org Lett       Date:  2012-08-14       Impact factor: 6.005

5.  Imidazole as a Promising Medicinal Scaffold: Current Status and Future Direction.

Authors:  Sahar S Alghamdi; Rasha S Suliman; Khlood Almutairi; Khawla Kahtani; Dimah Aljatli
Journal:  Drug Des Devel Ther       Date:  2021-07-29       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.